NEWS

Ayala Pharmaceuticals

As part of a larger collaboration, Ayala Pharmaceuticals has chosen Tempus as the preferred sequencing partner to support in screening and recruiting patients for its TENACITY AL101 study, a therapy targeting triple negative breast cancer. The collaboration aims to identify patients with various NOTCH alterations to accurately match and enroll them into the TENACITY trial operating in the U.S., Euro...